Evidence map›Paper›PMID 38089252›Full record

ArticleJournal of mass spectrometry and advances in the clinical lab2023

Exploring

Jonathan Zintgraff, Florencia Rocca, Nahuel Sánchez Eluchans, Lucía Irazu, Maria Alicia Moscoloni, Claudia Lara, Mauricio Santos

Open access · goldAbstract read
In one paragraph

Article in Journal of mass spectrometry and advances in the clinical lab, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jonathan ZintgraffServicio Bacteriología Clínica, Instituto Nacional de Enfermedades Infecciosas (INEI)- Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G. Malbrán", Buenos Aires, Argentina.
Florencia RoccaInstituto Nacional de Enfermedades Infecciosas (INEI) - Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G. Malbrán", Buenos Aires, Argentina.
Nahuel Sánchez EluchansServicio Bacteriología Clínica, Instituto Nacional de Enfermedades Infecciosas (INEI)- Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G. Malbrán", Buenos Aires, Argentina.
Lucía IrazuInstituto Nacional de Enfermedades Infecciosas (INEI) - Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G. Malbrán", Buenos Aires, Argentina.
Maria Alicia MoscoloniServicio Bacteriología Clínica, Instituto Nacional de Enfermedades Infecciosas (INEI)- Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G. Malbrán", Buenos Aires, Argentina.
Claudia LaraServicio Bacteriología Clínica, Instituto Nacional de Enfermedades Infecciosas (INEI)- Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G. Malbrán", Buenos Aires, Argentina.
Mauricio SantosServicio Bacteriología Clínica, Instituto Nacional de Enfermedades Infecciosas (INEI)- Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G. Malbrán", Buenos Aires, Argentina.
Administración Nacional de Laboratorios e Institutos de Salud · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Laboratory surveillance of Objectives: In this study, we aimed to investigate the viability of utilizing MALDI-TOF MS technology as an adjunctive and screening method for capsular typing of Methods: Firstly, we established a comprehensive spectral database comprising isolates of serotypes present in the PCV13 vaccine, along with the top 10 most prevalent NON PCV13 serotypes based on local epidemiological data. This database served as a foundation for developing unsupervised models utilizing MALDI-TOF MS spectra, which enabled us to identify inherent patterns and relationships within the data. Our analysis involved a dataset comprising 215 new isolates collected from nationwide surveillance in Argentina. Our approach involved developing classification models based on MALDI-TOF MS to discern between Results: Although our findings revealed suboptimal performance in serotype classification, they provide valuable insights into the potential of machine learning algorithms in this context. The sensitivity of the models ranged from 0.41 to 0.46, indicating their ability to detect certain serotypes. The observed specificity consistently remained at 0.60, suggesting a moderate level of accuracy in identifying non-vaccine serotypes. These results highlight the need for further refinement and optimization of the algorithms to enhance their discriminative power and predictive accuracy in serotype identification.By addressing the limitations identified in this study, such as exploring alternative feature selection techniques or optimizing algorithm parameters, we can unlock the full potential of machine learning in robust and reliable serotype classification of Conclusion: Overall, our study contributes to the growing body of research on utilizing MALDI-TOF MS and machine learning algorithms for serotype identification purposes.

Indexed as

Capsular typingConjugates vaccinesMachine learningMALDI TOFMass spectrometryStreptococcus pneumonia

Identifiers

PMID38089252
PMCPMC10711160
OpenAlexW4389000739

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.